T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.
Competing Interests: Declaration of competing interest Bernard Zinman has received financial support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Sanofi. Christoph Wanner has served as a consultant and/or member of clinical trial steering committees for AstraZeneca, Bayer, Boehringer Ingelheim and Merck Sharp & Dohme. He has delivered lectures sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme and Mitsubishi. Silvio E. Inzucchi has received honoraria for lectures, advisory work and/or clinical trial leadership from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Merck, Pfizer and Bayer.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)